| Clinical effectiveness and safety of erythropoietin‐stimulating agents for the treatment of low‐and intermediate‐1− risk myelodysplastic syndrome: a systematic literature review S Park, P Greenberg, A Yucel, C Farmer, F O'Neill, C De Oliveira Brandao, ... British journal of haematology 184 (2), 134-160, 2019 | 56 | 2019 |
| Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial AT Taher, MD Cappellini, A Kattamis, E Voskaridou, S Perrotta, AG Piga, ... The Lancet Haematology 9 (10), e733-e744, 2022 | 35 | 2022 |
| Adverse drug reactions due to drug–drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method E Yucel, M Sancar, A Yucel, B Okuyan Expert opinion on drug safety 15 (2), 223-236, 2016 | 33 | 2016 |
| Estimating the economic burden of migraine on US employers. A Yucel, A Thach, S Kumar, C Loden, M Bensink, N Goldfarb The American Journal of Managed Care 26 (12), e403-e408, 2020 | 29 | 2020 |
| Validation of the Turkish version of medication regimen complexity index among elderly patients B Okuyan, B Babi, M Sancar, P Ay, E Yücel, A Yücel, FV Izzettin Journal of evaluation in clinical practice 22 (5), 732-736, 2016 | 26 | 2016 |
| Racial/ethnic differences in treatment quality among youth with primary care provider‐initiated versus mental health specialist‐initiated care for major depressive disorders A Yucel, S Sanyal, EJ Essien, O Mgbere, R Aparasu, VS Bhatara, ... Child and adolescent mental health 25 (1), 28-35, 2020 | 11 | 2020 |
| Relationship between serum ferritin and outcomes in β-thalassemia: a systematic literature review F Shah, K Huey, S Deshpande, M Turner, M Chitnis, E Schiller, A Yucel, ... Journal of Clinical Medicine 11 (15), 4448, 2022 | 9 | 2022 |
| A systematic literature review of the relationship between serum ferritin and outcomes in myelodysplastic syndromes EN Oliva, K Huey, S Deshpande, M Turner, M Chitnis, E Schiller, D Tang, ... Journal of Clinical Medicine 11 (3), 895, 2022 | 8 | 2022 |
| Racial/ethnic differences in the treatment of adolescent major depressive disorders (MDD) across healthcare providers participating in the Medicaid program A Yucel, EJ Essien, S Sanyal, O Mgbere, RR Aparasu, VS Bhatara, ... Journal of Affective Disorders 235, 155-161, 2018 | 7 | 2018 |
| Benefit of continuing therapy with luspatercept in patients with β-thalassemia who do not achieve≥ 33% reduction in red blood cell transfusion burden in weeks 13–24 in the … A Piga, MD Cappellini, JB Porter, O Hermine, KHM Kuo, TD Coates, ... HemaSphere 5 (Suppl 2), 631, 2021 | 5 | 2021 |
| The long-term social value of granulocyte colony-stimulating factors AR Silverstein, MS Emma van Eijndhoven, C Bowers, M Bensink, ... Am J Manag Care 25 (10), 486-493, 2019 | 5 | 2019 |
| Patients' beliefs regarding counseling provided by community pharmacists: an application of the theory of planned behavior ML Fleming, EA Ferries, MD Hatfield, N Atreja, A Yucel, PP Rane, ... Journal of Pharmaceutical Health Services Research 6 (1), 77-79, 2015 | 5 | 2015 |
| Health‐related quality of life in patients with β‐thalassemia: Data from the phase 3 BELIEVE trial of luspatercept MD Cappellini, AT Taher, A Piga, F Shah, E Voskaridou, V Viprakasit, ... European Journal of Haematology 111 (1), 113-124, 2023 | 4 | 2023 |
| Development and content validation of the Satisfaction and Experience Questionnaire for Granulocyte Colony-Stimulating factor (SEQ-G-CSF) A Yucel, A Skalicky, OR Eseyin, E Yucel, R Belani, M Bensink Journal of Patient-Reported Outcomes 5 (1), 1-13, 2021 | 4 | 2021 |
| Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study U Germing, P Fenaux, U Platzbecker, R Buckstein, V Santini, ... Annals of Hematology 102 (2), 311-321, 2023 | 3 | 2023 |
| Analysis of duration of response, exposure-adjusted safety and progression to acute myeloid leukemia (AML) for patients with lower-risk myelodysplastic syndromes (LR-MDS … U Platzbecker, V Santini, RS Komrokji, AM Zeidan, G Garcia-Manero, ... Blood 138, 1524, 2021 | 3 | 2021 |
| Luspatercept improves quality of life and reduces red blood cell transfusion burden in patients with non-transfusion-dependent β-thalassemia in the BEYOND trial A Kattamis, V Viprakasit, MD Cappellini, E Voskaridou, A Piga, JB Porter, ... Blood 138, 3081, 2021 | 3 | 2021 |
| Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or-intolerant patients with lower-risk myelodysplastic … U Platzbecker, V Santini, RS Komrokji, AM Zeidan, G Garcia-Manero, ... Leukemia 37 (11), 2314-2318, 2023 | 2 | 2023 |
| Overall survival and progression-free survival of patients following luspatercept treatment in the MEDALIST trial V Santini, P Fenaux, AM Zeidan, RS Komrokji, R Buckstein, EN Oliva, ... Blood 140 (Supplement 1), 4079-4081, 2022 | 2 | 2022 |
| Fewer red blood cell transfusion units and visits across baseline transfusion burden levels in patients with beta-thalassemia treated with luspatercept in the phase 3 believe trial AT Taher, JB Porter, O Hermine, A Piga, TD Coates, A Kattamis, A Khelif, ... 26th Congress of the European Hematology Association (EHA), 2021 | 2 | 2021 |
Rajender R. Aparasu, PhD, FAPhADepartment of Pharmaceutical Health Outcomes and Policy - University of Houston College of PharmacyVerified email at uh.edu
